Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Wyeth under the tradename Viviant. Bazedoxifene's combination with conjugated estrogens, Aprela, is currently undergoing Phase III studies.
0 edits since May 19, 2008. Last edited May 05, 2008 by Chowbok (100).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Bazedoxifene. See this site's terms for details.